Arbutus Biopharma Corporation (ABUS)
ABUS Stock Price Chart
Explore Arbutus Biopharma Corporation interactive price chart. Choose custom timeframes to analyze ABUS price movements and trends.
ABUS Company Profile
Discover essential business fundamentals and corporate details for Arbutus Biopharma Corporation (ABUS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jul 2007
Employees
44.00
Website
https://www.arbutusbio.comCEO
Lindsay Androski
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
ABUS Financial Timeline
Browse a chronological timeline of Arbutus Biopharma Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.02, while revenue estimate is $1.31M.
Earnings released on 6 Aug 2025
EPS came in at $0.01 surpassing the estimated -$0.02 by +150.00%, while revenue for the quarter reached $10.74M , beating expectations by +574.98%.
Earnings released on 14 May 2025
EPS came in at -$0.13 falling short of the estimated -$0.09 by -44.44%, while revenue for the quarter reached $1.76M , missing expectations by -21.32%.
Earnings released on 27 Mar 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%, while revenue for the quarter reached $1.57M , missing expectations by -30.26%.
Earnings released on 6 Nov 2024
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $1.34M , missing expectations by -15.25%.
Earnings released on 1 Aug 2024
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%, while revenue for the quarter reached $1.73M , missing expectations by -6.70%.
Earnings released on 2 May 2024
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $1.53M , missing expectations by -28.74%.
Earnings released on 29 Feb 2024
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $2.15M , missing expectations by -55.22%.
Earnings released on 7 Nov 2023
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $4.66M , missing expectations by -2.76%.
Earnings released on 3 Aug 2023
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%, while revenue for the quarter reached $4.65M , missing expectations by -24.50%.
Earnings released on 4 May 2023
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $6.69M , beating expectations by +10.90%.
Earnings released on 2 Mar 2023
EPS came in at -$0.14 matching the estimated -$0.14, while revenue for the quarter reached $6.25M , beating expectations by +1.13%.
Earnings released on 9 Nov 2022
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $5.95M , missing expectations by -36.51%.
Earnings released on 4 Aug 2022
EPS came in at -$0.10 surpassing the estimated -$0.13 by +23.08%, while revenue for the quarter reached $14.24M , beating expectations by +110.43%.
Earnings released on 5 May 2022
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $12.58M , beating expectations by +188.03%.
Earnings released on 3 Mar 2022
EPS came in at -$0.15 surpassing the estimated -$0.16 by +6.25%, while revenue for the quarter reached $3.21M , beating expectations by +11.21%.
Earnings released on 4 Nov 2021
EPS came in at -$0.24 matching the estimated -$0.24, while revenue for the quarter reached $3.34M , beating expectations by +40.34%.
Earnings released on 5 Aug 2021
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%, while revenue for the quarter reached $2.33M , beating expectations by +9.86%.
Earnings released on 5 May 2021
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%, while revenue for the quarter reached $2.11M , missing expectations by -35.97%.
Earnings released on 4 Mar 2021
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%, while revenue for the quarter reached $2.39M , beating expectations by +17.54%.
Earnings released on 5 Nov 2020
EPS came in at -$0.27 falling short of the estimated -$0.20 by -35.00%, while revenue for the quarter reached $1.52M , beating expectations by +22.73%.
ABUS Stock Performance
Access detailed ABUS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.